Real ChatGPT answer · index seedyGPtaGROx04completeHealth and wellness · women's healthinformational
How long do menopause symptoms typically last and what are the newest non hormonal prescription treatments available for relief
Download run
Fan-out diagram
The searches the AI actually ran for this prompt.
SEED QUERY
How long do menopause symptoms typically last and what are the newest non hormonal prescription treatments available for relief
2 real searches · 1 real-search pass
2026 latest FDA approved nonhormonal treatments menopause vasomotor symptoms fezolinetant elinzanetant approval FDA 2025 2026Google ↗
OBSERVED
NAMS nonhormone therapy position statement menopause hot flashes oxybutynin gabapentin SSRIs fezolinetant duration symptoms SWAN study 7.4 yearsGoogle ↗
OBSERVED
Badge and edge weight = share of passes that produced the query. Hover a query for its intent and routing format.
Query classes
Google's semantic query class for every sub-query: what kind of answer each search is after, simulated vs real.
Classifying 2 queries…
Searches and sources
ChatGPT2 real searches · gpt-6
2026 latest FDA approved nonhormonal treatments menopause vasomotor symptoms fezolinetant elinzanetant approval FDA 2025 2026 Google ↗
NAMS nonhormone therapy position statement menopause hot flashes oxybutynin gabapentin SSRIs fezolinetant duration symptoms SWAN study 7.4 years Google ↗
- Drug Trials Snapshots: LYNKUET · fda.gov
- DailyMed · dailymed.nlm.nih.gov
- ACOG Clinical Practice Guideline: Management of... : Obstetrics & Gynecology · doi.org
- FDA adds warning about rare occurrence of serious liver injury with use of Veozah (fezolinetant) for hot flashes due to menopause · fda.gov
- The 2023 nonhormone therapy position statement of The North American Menopause Society · pubmed.ncbi.nlm.nih.gov
Queries
2 queries · click a column to sort
| Query / type | Search | Intent | Query class | Routing format | Cluster | Freq ↓ | Weight |
|---|---|---|---|---|---|---|---|
2026 latest FDA approved nonhormonal treatments menopause vasomotor symptoms fezolinetant elinzanetant approval FDA 2025 2026 OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 | |
NAMS nonhormone therapy position statement menopause hot flashes oxybutynin gabapentin SSRIs fezolinetant duration symptoms SWAN study 7.4 years OBSERVED | Google ↗ AI Mode ↗ | — | — | — | — | 1x of 1 |